SPL-8423 is under clinical development by SpliSense and currently in Phase II for Cystic Fibrosis. According to GlobalData, Phase II drugs for Cystic Fibrosis have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SPL-8423’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SPL84-23-1 is under development for the treatment of cystic fibrosis with 3849+10 kb C-to-T mutation. The drug candidate is an antisense oligonucleotide (ASO) and is administered by inhalational route.
SpliSense develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. SpliSense is headquartered in Jerusalem, Israel.
For a complete picture of SPL-8423’s drug-specific PTSR and LoA scores, buy the report here.